Want to see SE:SPAGO full AI Analyst Report?

Spago Nanomedical AB (SPAGO) Price & Analysis

0 Followers

SPAGO Stock Chart & Stats

kr0.10

kr0.00(0.00%)

At close: Mar 06 4:00 PM EST

kr0.10

kr0.00(0.00%)

Day’s Range― - ―

52-Week Rangekr0.08 - kr0.26

Previous CloseN/A

Volume33.85K

Average Volume (3M)1.01M

Market Cap

kr94.60M

Enterprise Valuekr11.85M

Total Cash (Recent Filing)kr25.92M

Total Debt (Recent Filing)kr0.00

Price to Earnings (P/E)―

Beta1.09

Next Earnings

Aug 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.06

Shares Outstanding808,588,800

10 Day Avg. Volume1,158,815

30 Day Avg. Volume1,005,829

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)1.42

Price to Sales (P/S)99.92

P/FCF Ratio-1.53

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-0.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetA consistent zero-debt position materially lowers solvency risk for a clinical-stage biotech. It preserves financial flexibility to fund R&D through equity or partnerships rather than interest-bearing borrowings, reducing fixed costs and supporting multi-stage clinical programs over months.

Focused Nanomedicine PipelineClear strategic focus on nanoparticle imaging (SpagoPix) and targeted radiotherapy (Tumorad) offers platform-level optionality. A dual diagnostic/therapeutic pipeline aligns with structural trends toward precision oncology and can create durable differentiation if clinical milestones validate the technology.

Improving Cash-burn TrendA reduction in operating cash outflows versus prior years indicates better cash management or milestone-driven spending discipline. That trend, if sustained, eases near-term funding pressure and extends runway, improving the firm's ability to reach clinical inflection points without immediate refinancing.

Bears Say

Sharp Revenue DeclineA ~72% TTM revenue drop signals weak commercialization or one-off revenues drying up, reducing internal funding capacity and increasing reliance on external capital. For a pre-commercial biotech, declining receipts undermine optionality and heighten financing and execution risk over coming quarters.

Persistent Negative Cash FlowChronic negative operating and free cash flow indicate the company consumes cash to sustain R&D with no offsetting internal cash generation. This structural cash burn necessitates periodic equity or partner funding, diluting shareholders and constraining long-term program investment choices.

Ongoing Large Operating LossesSustained, material operating losses demonstrate limited operating leverage and that scale has not been achieved. Continued capital consumption erodes equity and increases the probability of future fundraising, which can delay or reshape clinical plans and impair long-term value creation.

SPAGO FAQ

What was Spago Nanomedical AB’s price range in the past 12 months?

Spago Nanomedical AB lowest stock price was kr0.08 and its highest was kr0.26 in the past 12 months.

What is Spago Nanomedical AB’s market cap?

Spago Nanomedical AB’s market cap is kr94.60M.

When is Spago Nanomedical AB’s upcoming earnings report date?

Spago Nanomedical AB’s upcoming earnings report date is Aug 20, 2026 which is in 45 days.

How were Spago Nanomedical AB’s earnings last quarter?

Spago Nanomedical AB released its earnings results on May 07, 2026. The company reported -kr0.01 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.01.

Is Spago Nanomedical AB overvalued?

According to Wall Street analysts Spago Nanomedical AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Spago Nanomedical AB pay dividends?

Spago Nanomedical AB does not currently pay dividends.

What is Spago Nanomedical AB’s EPS estimate?

Spago Nanomedical AB’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Spago Nanomedical AB have?

Spago Nanomedical AB has 808,588,800 shares outstanding.

What happened to Spago Nanomedical AB’s price movement after its last earnings report?

Spago Nanomedical AB reported an EPS of -kr0.01 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.348%.

Which hedge fund is a major shareholder of Spago Nanomedical AB?

Currently, no hedge funds are holding shares in SE:SPAGO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Spago Nanomedical AB

Operating primarily in Sweden, Spago Nanomedical AB (publ) is dedicated to pioneering nanomedicines for both the diagnosis and treatment of cancer. The company is actively pursuing two key projects: the SpagoPix initiative, centered on SN132D, a gadolinium-free MRI contrast agent developed for imaging breast and pancreatic cancers; and the Tumorad project, which is advancing SN201, a radionuclide therapy intended for managing advanced and metastatic forms of cancer. Originally established as Spago Imaging AB (publ), the company adopted its current name, Spago Nanomedical AB (publ), in May 2014. Founded in 1999, its base of operations is situated in Lund, Sweden.